A detailed history of Pro Share Advisors LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 18,917 shares of FATE stock, worth $43,319. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,917
Previous 11,351 66.65%
Holding current value
$43,319
Previous $37,000 78.38%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.12 - $5.57 $23,605 - $42,142
7,566 Added 66.65%
18,917 $66,000
Q2 2024

Aug 13, 2024

SELL
$3.26 - $7.08 $12,635 - $27,442
-3,876 Reduced 25.45%
11,351 $37,000
Q1 2024

May 08, 2024

BUY
$3.54 - $8.35 $4,244 - $10,011
1,199 Added 8.55%
15,227 $111,000
Q4 2023

Feb 14, 2024

SELL
$1.65 - $3.94 $5,649 - $13,490
-3,424 Reduced 19.62%
14,028 $52,000
Q3 2023

Nov 13, 2023

BUY
$2.02 - $5.04 $127 - $317
63 Added 0.36%
17,452 $36,000
Q2 2023

Aug 10, 2023

BUY
$4.76 - $6.59 $3,808 - $5,272
800 Added 4.82%
17,389 $82,000
Q1 2023

May 11, 2023

SELL
$4.24 - $11.12 $14,390 - $37,741
-3,394 Reduced 16.98%
16,589 $94,000
Q4 2022

Feb 02, 2023

BUY
$9.86 - $23.83 $13,281 - $32,099
1,347 Added 7.23%
19,983 $201,000
Q3 2022

Nov 04, 2022

BUY
$21.04 - $36.06 $8,984 - $15,397
427 Added 2.34%
18,636 $418,000
Q2 2022

Aug 01, 2022

SELL
$17.78 - $42.39 $157,246 - $374,897
-8,844 Reduced 32.69%
18,209 $450,000
Q1 2022

May 10, 2022

SELL
$29.67 - $60.28 $182,618 - $371,023
-6,155 Reduced 18.53%
27,053 $1.05 Million
Q4 2021

Feb 08, 2022

BUY
$47.84 - $64.34 $26,886 - $36,159
562 Added 1.72%
33,208 $1.94 Million
Q3 2021

Nov 12, 2021

SELL
$59.27 - $95.73 $297,298 - $480,181
-5,016 Reduced 13.32%
32,646 $1.94 Million
Q2 2021

Aug 13, 2021

BUY
$67.25 - $92.52 $293,210 - $403,387
4,360 Added 13.09%
37,662 $3.27 Million
Q1 2021

May 14, 2021

BUY
$72.16 - $117.4 $286,403 - $465,960
3,969 Added 13.53%
33,302 $2.75 Million
Q4 2020

Feb 09, 2021

BUY
$38.09 - $100.95 $249,832 - $662,131
6,559 Added 28.8%
29,333 $2.67 Million
Q3 2020

Nov 13, 2020

BUY
$30.41 - $40.5 $56,136 - $74,763
1,846 Added 8.82%
22,774 $910,000
Q2 2020

Aug 03, 2020

BUY
$20.21 - $35.23 $140,944 - $245,694
6,974 Added 49.98%
20,928 $718,000
Q1 2020

May 15, 2020

SELL
$17.28 - $31.88 $183,427 - $338,406
-10,615 Reduced 43.2%
13,954 $310,000
Q4 2019

Feb 12, 2020

BUY
$13.39 - $20.73 $12,613 - $19,527
942 Added 3.99%
24,569 $481,000
Q3 2019

Nov 12, 2019

SELL
$15.47 - $22.5 $28,186 - $40,995
-1,822 Reduced 7.16%
23,627 $367,000
Q2 2019

Aug 13, 2019

SELL
$15.61 - $20.44 $47,829 - $62,628
-3,064 Reduced 10.75%
25,449 $517,000
Q1 2019

May 15, 2019

BUY
$13.15 - $18.71 $3,195 - $4,546
243 Added 0.86%
28,513 $501,000
Q4 2018

Feb 14, 2019

BUY
$11.48 - $16.98 $324,539 - $480,024
28,270 New
28,270 $363,000

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.